I-MOVE-plus project deliverables
The page lists 31 deliverables related to the research project "I-MOVE-plus".
List of Deliverables
| title and desprition | type | last update |
|---|---|---|
Third End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Scientific communicationSummarise lessons learned as regards the use of electronic databases. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Submission of article summarising the I-MOVE+ experience in evaluating the influenza vaccines, results and perspective for the future.At the end of the three year project, a summary article will be written summarising all the lessons learnt, the results of the research questions addressed (effect of previous vaccinations, duration of protection). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Third Report I-MOVE+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Scientific manuscript WP4Scientific manuscript that presents 1) the results from the comparison of influenza VE estimates using different methods on the same database 2) Effect of previous influenza vaccinations on current influenza VE. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Scientific Manuscript WP5Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Third Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Training material available.A set of training material will be available on the website addressing methodological issues of studies measuring the effects of the influenza vaccine and data analysis. The training material will include presentations, case studies and programmes for data analysis. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Report on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidenceA report presenting the joint analyses on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidence will be provided. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Third Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
One manuscript submitted for publication and/or abstracts for at least one conference.Studies results will be prepared for publication/presentations. At least one manuscript and at least one abstract will be prepared and submitted to relevant journals and conferences. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Report with description of influenza and pneumococcal outcomes in each database.The report includes A) Descriptions of influenza outcomes in each database, including detailed information on methods used for detection and subtyping in each county. Description of information on vaccines (product name, repeated vaccination eg) and level of information on risk factors and confounders. B) The comparability of the databases is explored in order to identify a common level of detail of information in the databases, which allows register-based studies across countries. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Second Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference.At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference. (Month 18, Month 30, Month 40) Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Generic protocols for effectiveness and impact studies of pneumococcal vaccinesThe generic protocols will include a description of study designs, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, sample size. They will specify the parts that each study site will have to document when writing the study site protocol. Generic protocols will detail the methods used and the plan of analysis to answer to specific research questions such as the duration of protection, magnitude of replacement etc. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Second Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First Report I-Move+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Second. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Written report including a generic cost-effectiveness modelWritten report including a generic cost-effectiveness model which can be used among the participating countries; Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications, Month 24. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Third. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Generic protocols to measure influenza vaccine effectiveness at primary care and hospital level, using a test-negative design and screening method.The generic protocols will include a description of the study design, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, the sample size. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
I-MOVE+ website with different access level and tools for internal collaboration, communicationAn I-MOVE+ website will be available with three levels of access: restricted to study sites conducting studies and ECDC, restricted to I-MOVE+ partners, and open to public. Study sites will exchange results using the restricted website area. In this restricted area, sites will update on a regular basis the number of individuals recruited in the studies. Preliminary results will be shared among relevant study sites during periodic videoconferences. The website will include a library of documents (protocols, articles, training material, videoconference minutes etc). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Websites, patent fillings, videos etc. | 2020-02-20 |
Second Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Third Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Second Report I-MOVE+ ST/Scientific MeetingsReport I-MOVE+ ST/Scientific Meetings Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Second End of season, pooled influenza vaccine effectiveness estimates report.The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First season Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc). Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
First season Study sites protocols to measure influenza vaccine impact in season.The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |
Generic protocol to measure impact of the seasonal influenza vaccineThe generic protocol will include the different settings and the populations to be compared to assess the different impact effects. Programme: H2020-EU.3.1.3. - Topic(s): PHC-17-2014 |
Documents, reports | 2020-02-20 |